Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAMELA L ALVAREZ

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1881627743
CMS profile
175686
Location
MURRIETA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,162.14

226 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,162.14 226

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAMELA L ALVAREZ

NPI 1881627743 · CMS profile ID 175686

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

MURRIETA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881627743?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAMELA L ALVAREZ, NPI 1881627743, CMS profile ID 175686. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881627743?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PAMELA L ALVAREZ, NPI 1881627743, CMS profile ID 175686. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881627743?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PAMELA L ALVAREZ, NPI 1881627743, CMS profile ID 175686, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 226 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1881627743?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

226 matching records · $3,162.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 226 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 226.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alexion Pharmaceuticals, Inc. $19.9909/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124531 CMS
AbbVie Inc. $19.7109/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872581 CMS
AbbVie Inc. $4.4709/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872585 CMS
Amgen Inc. $28.9809/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825672229 CMS
Teva Pharmaceuticals USA, Inc. $4.0609/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517687 CMS
Teva Pharmaceuticals USA, Inc. $9.2409/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517689 CMS
Genentech USA, Inc. $19.5409/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835960227 CMS
Sunovion Pharmaceuticals Inc. $19.9909/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821657859 CMS
AbbVie Inc. $12.8609/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872577 CMS
Teva Pharmaceuticals USA, Inc. $2.7709/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517683 CMS
Teva Pharmaceuticals USA, Inc. $9.3309/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517685 CMS
AstraZeneca Pharmaceuticals LP $12.6509/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829782603 CMS
UCB, Inc. $30.2609/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807456335 CMS
Greenwich Biosciences, Inc. $17.8109/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841840347 CMS
AbbVie Inc. $8.4609/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872565 CMS
AbbVie Inc. $8.0309/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872569 CMS
AbbVie Inc. $4.1809/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872573 CMS
Teva Pharmaceuticals USA, Inc. $12.9909/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517681 CMS
AbbVie Inc. $9.0809/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872557 CMS
AbbVie Inc. $4.6209/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872561 CMS
Amgen Inc. $33.0909/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825672225 CMS
ACADIA Pharmaceuticals Inc $18.2209/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837987977 CMS
Teva Pharmaceuticals USA, Inc. $14.7209/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517679 CMS
Novartis Pharmaceuticals Corporation $11.9109/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812586389 CMS
AstraZeneca Pharmaceuticals LP $22.1709/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829778579 CMS
AbbVie Inc. $6.9308/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872553 CMS
Teva Pharmaceuticals USA, Inc. $11.3008/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517677 CMS
Amgen Inc. $6.4408/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825672221 CMS
AbbVie Inc. $23.8708/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872549 CMS
Eisai Inc. $20.7608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817987341 CMS
AbbVie Inc. $6.2808/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872545 CMS
Teva Pharmaceuticals USA, Inc. $30.1408/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517675 CMS
GENZYME CORPORATION $18.2808/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843592193 CMS
Biohaven Pharmaceuticals, Inc. $9.7008/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852402589 CMS
Teva Pharmaceuticals USA, Inc. $11.8608/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517673 CMS
Novartis Pharmaceuticals Corporation $14.8908/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812586387 CMS
AbbVie Inc. $20.6508/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872541 CMS
Teva Pharmaceuticals USA, Inc. $7.1508/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517671 CMS
UCB, Inc. $6.3607/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807319637 CMS
Biohaven Pharmaceuticals, Inc. $25.9807/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852402585 CMS
AbbVie Inc. $15.0907/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872533 CMS
AbbVie Inc. $3.2507/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872537 CMS
Teva Pharmaceuticals USA, Inc. $7.7807/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517669 CMS
Biogen, Inc. $18.8907/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827782699 CMS
AbbVie Inc. $24.6007/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872529 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.7507/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819850133 CMS
Teva Pharmaceuticals USA, Inc. $9.2507/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839517667 CMS
AbbVie Inc. $5.3307/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872521 CMS
AbbVie Inc. $1.8807/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793872525 CMS
Janssen Biotech, Inc. $16.9207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788782131 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,428.23 161
PY2020 $1,938.62 118
PY2021 $3,162.14 226
PY2022 $3,533.12 231
PY2023 $3,038.74 163
PY2024 $3,000.34 156
PY2025 $2,372.85 128

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $536,650.08 88
PY2024 Principal investigator $482,741.34 80
PY2023 Principal investigator $323,627.97 74
PY2022 Principal investigator $453.61 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,402.52 12/31/2025 Non-covered Recipient Entity
VIKING CLINICAL RESEARCH
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202534229
Principal investigator 1 ABBVIE INC. $3,758.96 12/31/2025 Non-covered Recipient Entity
VIKING CLINICAL RESEARCH
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies No dispute reported 06/30/2026 1202534231
Principal investigator 1 ABBVIE INC. $1,592.56 12/31/2025 Non-covered Recipient Entity
VIKING CLINICAL RESEARCH
Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202534233
Principal investigator 1 ABBVIE INC. $79.59 12/23/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202531696
Principal investigator 1 Janssen Research & Development, LLC $20,888.00 12/18/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415227
Principal investigator 1 Janssen Research & Development, LLC $57.00 12/05/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415116
Principal investigator 1 Janssen Research & Development, LLC $553.00 12/05/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415254
Principal investigator 1 Janssen Research & Development, LLC $75.91 12/05/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415284
Principal investigator 1 ABBVIE INC. $24,006.71 12/04/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202526484
Principal investigator 1 ABBVIE INC. $5,000.00 12/04/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202526576
Principal investigator 1 ABBVIE INC. $2,690.55 12/04/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202526578
Principal investigator 1 Vanda Pharmaceuticals Inc. $4,250.00 12/04/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder No dispute reported 06/30/2026 1232947112
Principal investigator 1 ABBVIE INC. $1,420.00 11/26/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202525472
Principal investigator 1 ABBVIE INC. $3,650.00 11/25/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202525246
Principal investigator 1 ABBVIE INC. $300.00 11/20/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202524806
Principal investigator 1 ABBVIE INC. $372.03 11/13/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202524091
Principal investigator 1 Janssen Research & Development, LLC $60.25 11/10/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415153
Principal investigator 1 ABBVIE INC. $40,992.75 11/05/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202521731
Principal investigator 1 Janssen Research & Development, LLC $7,145.00 10/27/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415290
Principal investigator 1 Janssen Research & Development, LLC $4,937.00 10/20/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415147
Principal investigator 1 ABBVIE INC. $47,618.62 10/09/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202516307
Principal investigator 1 ABBVIE INC. $355.78 10/09/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202516309
Principal investigator 1 Janssen Research & Development, LLC $273.00 10/09/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415142
Principal investigator 1 Janssen Research & Development, LLC $13,400.00 09/29/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415199
Principal investigator 1 ABBVIE INC. $159.31 09/18/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202511588
Principal investigator 1 ABBVIE INC. $319.42 09/11/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202510782
Principal investigator 1 Janssen Research & Development, LLC $5,667.00 09/05/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415123
Principal investigator 1 ABBVIE INC. $750.00 09/04/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202509884
Principal investigator 1 ABBVIE INC. $29,161.35 09/04/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202509886
Principal investigator 1 ABBVIE INC. $198.53 09/04/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202509888
Principal investigator 1 ABBVIE INC. $945.00 09/04/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202509950
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,853.11 09/03/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder No dispute reported 06/30/2026 1232946188
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 08/29/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415301
Principal investigator 1 ABBVIE INC. $69.63 08/18/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202504987
Principal investigator 1 ABBVIE INC. $95.04 08/12/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202504223
Principal investigator 1 Vanda Pharmaceuticals Inc. $250.00 08/08/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder No dispute reported 06/30/2026 1232946099
Principal investigator 1 ABBVIE INC. $4,392.90 08/06/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202502422
Principal investigator 1 Janssen Research & Development, LLC $436.00 08/01/2025 Non-covered Recipient Entity
Viking Clnc Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175181364
Principal investigator 1 ABBVIE INC. $129.92 07/31/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202500560
Principal investigator 1 Janssen Research & Development, LLC $620.00 07/28/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415328
Principal investigator 1 ABBVIE INC. $5,000.00 07/24/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202499476
Principal investigator 1 ABBVIE INC. $800.00 07/24/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202499478
Principal investigator 1 Janssen Research & Development, LLC $5,302.00 07/14/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415312
Principal investigator 1 ABBVIE INC. $147.15 07/09/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202497560
Principal investigator 1 Janssen Research & Development, LLC $327.00 07/07/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415165
Principal investigator 1 Janssen Research & Development, LLC $5,302.00 07/07/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415188
Principal investigator 1 ABBVIE INC. $10,582.65 07/02/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202494015
Principal investigator 1 Vanda Pharmaceuticals Inc. $8,307.91 07/01/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder No dispute reported 06/30/2026 1232945624
Principal investigator 1 Janssen Research & Development, LLC $2,606.00 06/30/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415135
Principal investigator 1 ABBVIE INC. $9,930.80 06/03/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202489721
Principal investigator 1 Janssen Research & Development, LLC $7,963.00 06/02/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415240
Principal investigator 1 Janssen Research & Development, LLC $2,209.00 05/26/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415215
Principal investigator 1 Janssen Research & Development, LLC $1,508.00 05/21/2025 Non-covered Recipient Entity
Viking Clnc Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175181370
Principal investigator 1 Janssen Research & Development, LLC $325.00 05/19/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415169
Principal investigator 1 Janssen Research & Development, LLC $5,302.00 05/19/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415183
Principal investigator 1 Janssen Research & Development, LLC $295.81 05/19/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415210
Principal investigator 1 Janssen Research & Development, LLC $423.00 05/19/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415264
Principal investigator 1 Janssen Research & Development, LLC $400.00 05/15/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415258
Principal investigator 1 ABBVIE INC. $2,000.00 05/07/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder No dispute reported 06/30/2026 1202483773
Principal investigator 1 ABBVIE INC. $16,822.75 05/07/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202483775
Principal investigator 1 ABBVIE INC. $340.56 05/06/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202482057
Principal investigator 1 Janssen Research & Development, LLC $20,677.00 05/05/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415321
Principal investigator 1 Vanda Pharmaceuticals Inc. $12,500.00 04/30/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder No dispute reported 06/30/2026 1232945339
Principal investigator 1 ABBVIE INC. $19,500.00 04/29/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202479829
Principal investigator 1 Janssen Research & Development, LLC $8,669.00 04/28/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415157
Principal investigator 1 Janssen Research & Development, LLC $2,986.00 04/23/2025 Non-covered Recipient Entity
Viking Clnc Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175181349
Principal investigator 1 Janssen Research & Development, LLC $4,331.00 04/21/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415195
Principal investigator 1 Janssen Research & Development, LLC $4,331.00 04/21/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415295
Principal investigator 1 Janssen Research & Development, LLC $5,284.00 04/07/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415278
Principal investigator 1 ABBVIE INC. $52.00 04/03/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202471200
Principal investigator 1 ABBVIE INC. $18,290.00 04/03/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202471362
Principal investigator 1 ABBVIE INC. $11,417.25 04/03/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202471366
Principal investigator 1 ABBVIE INC. $1,000.00 04/02/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202468438
Principal investigator 1 Janssen Research & Development, LLC $1,660.00 04/02/2025 Non-covered Recipient Entity
Viking Clnc Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175181341
Principal investigator 1 Janssen Research & Development, LLC $3,364.00 03/31/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415222
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 03/31/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415271
Principal investigator 1 Janssen Research & Development, LLC $22,105.00 03/27/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415234
Principal investigator 1 Janssen Research & Development, LLC $1,398.00 03/14/2025 Non-covered Recipient Entity
Viking Clnc Rsrch
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175181356
Principal investigator 1 Janssen Research & Development, LLC $152.76 03/07/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415205
Principal investigator 1 Janssen Research & Development, LLC $2,700.00 03/05/2025 Non-covered Recipient Entity
Viking Clnc Rsrch
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175181382
Principal investigator 1 ABBVIE INC. $2,330.00 03/04/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202455731
Principal investigator 1 Janssen Research & Development, LLC $14,050.00 03/03/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415176
Principal investigator 1 Janssen Research & Development, LLC $3,945.00 02/28/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415245
Principal investigator 1 Janssen Research & Development, LLC $1,660.00 02/24/2025 Non-covered Recipient Entity
Viking Clnc Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175181390
Principal investigator 1 Janssen Research & Development, LLC $454.00 02/17/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415306
Principal investigator 1 Janssen Research & Development, LLC $19,500.00 02/10/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175415316
Principal investigator 1 Janssen Research & Development, LLC $9,415.00 01/27/2025 Non-covered Recipient Entity
VIKING PHARMACEUTICAL TRIALS INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175415129
Principal investigator 1 Janssen Research & Development, LLC $2,558.00 01/24/2025 Non-covered Recipient Entity
Viking Clnc Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175181377